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Abstract
Background: During period of crisis, laboratory planners may be faced with a need to make operational and
clinical decisions in the face of limited information. To avoid this dilemma, our laboratory utilizes a secure web
based platform, Data Integration for Alberta Laboratories (DIAL) to make near real-time decisions.
This manuscript utilizes the data collected by DIAL as well as laboratory test cost modeling to identify the relative
economic impact of four proposed scenarios of testing for Pandemic H1N1 (2009) and other respiratory viral
pathogens.
Methods: Historical data was collected from the two waves of the pandemic using DIAL. Four proposed molecular
testing scenarios were generated: A) Luminex respiratory virus panel (RVP) first with/without US centers for Disease
Control Influenza A Matrix gene assay (CDC-M), B) CDC-M first with/without RVP, C) RVP only, and D) CDC-M only.
Relative cost estimates of different testing algorithm were generated from a review of historical costs in the lab
and were based on 2009 Canadian dollars.
Results: Scenarios A and B had similar costs when the rate of influenza A was low (< 10%) with higher relative
cost in Scenario A with increasing incidence. Scenario A provided more information about mixed respiratory virus
infection as compared with Scenario B.
Conclusions: No one approach is applicable to all conditions. Testing costs will vary depending on the test
volume, prevalence of influenza A strains, as well as other circulating viruses and a more costly algorithm involving
a combination of different tests may be chosen to ensure that tests results are returned to the clinician in a
quicker manner. Costing should not be the only consideration for determination of laboratory algorithms.
Keywords: influenza, testing, relative comparisons, test algorithms, economic impact
Background
The influenza pandemic of 2009-2010 was probably the
most-prepared for pandemic in Canadian history [1]. In
Canada, much of this preparedness relied on the use of
molecular technologies for the detection of viral patho-
gens, including influenza. These tests are highly sensitive
for the detection of viral pathogens when compared to
traditional culture based or antigen-detection methods
[2-4]. A key dilemma of commercial multiplexed ver-
sions of these tests, which detect multiple pathogens, is
the relatively high cost. In contrast, “home-brew” meth-
ods to detect influenza are often less costly but cannot
detect other respiratory viral pathogens thus may have
limited applications when other respiratory viral patho-
gens are circulating and/or the prevalence of influenza
is low. Moreover, at the start of the pandemic, the per-
formance characteristics of various diagnostic assays
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ning for a pandemic response should take into account
factors such as test characteristics, test cost, prevalence
of pathogens and the diagnostic and clinical require-
ments of the end user.
The Province of Alberta, Canada has a population of 3.7
million (est. July 2010) [6] and the Provincial Laboratory
for Public Health, ProvLab, supports the pandemic plans
of this jurisdiction and surrounding Northern Territories
by providing molecular detection of Influenza A as well as
other respiratory viral pathogens. Real-time and retrospec-
tive data analysis and integration of laboratory results
within ProvLab is enabled through a secure, interactive
web based platform called DIAL (Data Integration for
Alberta Laboratories), which enables customized trending
(graphs, tables, or map) including integrated multi-virus
analysis and quick data extraction of cleaned and inter-
preted respiratory virus data generated at ProvLab [7].
ProvLab has access to monoplex assays designed only
for influenza A and B as well as multiplexed assays for
influenza A and B and other respiratory viral pathogens.
Influenza subtype analysis for seasonal H1 and H3 influ-
enza is available on monoplex assays and on multiplexed
respiratory viral pathogen panels [8]. This laboratory also
utilizes “home-brew” monoplex assays for the confirma-
tion of the Pandemic (H1N1) 2009 virus [9].
During a pandemic, one of the key issues facing diagnos-
tic testing laboratories is how to utilize laboratory tests in
the most cost-effective manner given the incredible work-
loads. This manuscript will utilize the data collected by
the DIAL system as well as laboratory test cost modeling
to identify the most cost-effective of four proposed scenar-
ios of testing for Pandemic H1N1 (2009) and other
respiratory viral pathogens. Beyond cost, advantages and
disadvantages to each scenario will be outlined.
Methods
Collection of historical data from two waves of the
pandemic
ProvLab was responsible for the majority of respiratory
virus detection within the Province. Raw laboratory testing
data for respiratory virus detection interpreted as clinically
meaningful respiratory virus targets were accessible real-
time on DIAL. Data for the prevalence of respiratory viral
pathogens was calculated on a weekly basis from April 19,
2009 to April 24, 2010.
Molecular tests included in the analysis
Prior to the pandemic, the Luminex respiratory virus
panel (RVP) was used at ProvLab to detect respiratory
virus on all DFA negative nasopharyngeal and lower
respiratory virus samples [9]. Real-time RT-PCR for
i n f l u e n z aAMg e n e( C D C - M ) ,r e a l - t i m eR T - P C Rf o r
influenza A seasonal subtypes H1 and H3, and ProvLab
developed real-time RT-PCR for Pandemic H1N1 (2009),
were rapidly implemented in the beginning of April 2009
as part of the Pandemic preparedness plan [5]. Perfor-
mance characteristics, sensitivity and specificity,o ft h e
different assays for Pandemic H1N1 (2009) were deter-
mined by analyzing the data extracted from DIAL. The
estimated sensitivities of each method for influenza A
virus were 98.6% (CI 96.5-99.6%) for CDC-M and 77.3%
(CI 72.1-82.1%) for RVP if equivocal influenza A result
by RVP were considered as negative for influenza A with
no further testing [10]. The specificity was 99.8% (CI
99.7-99.9%) for CDC-M and 99.8% (CI 99.8-99.9%) for
RVP.
Molecular testing algorithms
Four approaches were included to estimate costs in the
laboratory using historical data. Scenario A was the testing
algorithm used from April 19, 2009 till June 23, 2009
whereby Scenario B was adopted after the analysis of the
data showed a higher sensitivity of CDC-M for influenza
A as compared to RVP.
Scenario A - RVP first with/without CDC-M (Fig-
ure 1): Testing for respiratory viruses by RVP first, and
if typed as seasonal influenza A then stop. If influenza
A-positive specimen is not-typeable on RVP, then per-
form CDC-M to confirm influenza result as well as
typing using real-time RT-PCR by first screening for
pH1N1, followed by subtyping for seasonal H1/H3 if
negative for pH1N1. If specimen is influenza A-nega-
tive then attempt influenza A detection by CDC-M
protocol with sub-typing of influenza A positive
samples
Scenario B - CDC-M first with/without RVP (Fig-
u r e2 ) :T e s t i n gf o ri n f l u e n z aAb yC D C - Mf i r s tw i t h
subtyping of influenza A positive samples and the test-
ing of influenza A-negative specimens by RVP.
Scenario C - RVP only (Figure 3): Only testing for
influenza and respiratory viruses by RVP. If influenza A
positive and typed as seasonal influenza by RVP, then
stop. If influenza A-positive specimen is not-typeable on
RVP, perform typing pH1N1 +/- seasonal H1/H3. If influ-
enza A is negative by RVP then no more testing.
Scenario D - CDC-M only (Figure 4): testing only for
influenza A by CDC-M, followed by pH1N1 typing and
then seasonal influenza typing in pH1N1-negative.
Estimation of costs for various test algorithms
Costs estimates of different testing algorithms (Figures 1,
2, 3, 4) were generated from a review of historical costs in
the laboratory and were based on 2009 Canadian dollars.
Factors include; total number of respiratory virus speci-
mens; expected % specimen positive for influenza A
detected by RVP; expected % specimen positive for
pH1N1, and expected % positive for seasonal H1 and H3
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positive for influenza A and not typeable because of low
viral titers; and % influenza A positive tested negative by
RVP but detected by CDC-M. Key assumptions are; 1)
costs include labor and reagent and not overhead costs, 2)
costs do not include shipment, billing costs, nor data entry
3) costs include extraction plus scenario of test indicated,
4) costs are for molecular testing only and do not include
culture nor DFA, and 5) the number of false-positive and
false-negative test results will be negligible and were not
included in the cost analysis. The weekly total cost were
calculated using actual number of specimens tested at
ProvLab and the numbers of influenza positive specimens
and their H-types during the study period. For the analy-
sis, weekly relative cost of the different algorithms was cal-
culated at each point in time for the study period as a
ratio of cost for each algorithm to the cost of the
algorithm with the lowest cost for each respective week
over the study period.
Formulas for Cost estimations:
A. Scenario A - RVP with/without CDC-M: Cost of a1 + Cost
of a2 + Cost of a3 (figure 1)
Cost of a1: Cost of RVP*No. of specimen*Proportion of
influenza A positive samples detected by RVP*Proportion
of influenza A positive samples that are seasonal H1/H3
Cost of a2: (Cost of RVP*No. of specimen*Proportion of
influenza A positive samples detected by RVP)*(1-Propor-
tion of influenza A positive samples that seasonal H1/H3)+
[(Cost of CDC-M + Cost of pH1N1 typing)*No. of speci-
men*Proportion of influenza A positive samples detected by
RVP*Proportion of influenza A positive samples that are
pH1N1)] + [(Cost of CDC-M + Cost of pH1N1 typing+ Cost
of seasonal H1N1 typing)*No. of specimen*Proportion of
influenza A positive samples detected by RVP*(1-Proportion
Figure 1 Scenario A - RVP with/without CDC-M.
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nal H1/H3)]
Cost of a3: [(Cost of RVP+ Cost of CDC-M)*No. of spe-
cimen*Proportion of influenza A positive samples tested
negative by RVP and positive by CDC-M]+[ Cost of
pH1N1 typing*No. of specimen*Proportion of influenza A
positive samples tested negative by RVP and positive by
CDC-M *Proportion of influenza A positive samples that
are pH1N1]+[ ( Cost of pH1N1 typing+ Cost of seasonal
H1N1 typing)*No. of specimen*(1-Proportion of influ-
enza A positive samples that are pH1N1 and seasonal
H1/H3)]
B) Scenario B - CDC-M with/without RVP: Cost of b1 + Cost
of b2 + Cost of b3 (figure 2)
Cost of b1: (Cost of CDC-M+ Cost of pH1N1 typing)*No.
of specimen*Proportion of influenza A positive samples
detected by CDC-M*Proportion of influenza A positive
samples that are pH1N1
Cost of b2: (Cost of CDC-M+ Cost of pH1N1 typing+
Cost of seasonal H1/H3 typing)*No. of specimen*Propor-
tion of influenza A positive samples detected by CDC-
M*Proportion of influenza A positive samples that are
SeasonalH1/H3
Cost of b3: (Cost of RVP+ Cost of CDC-M)*No. of spe-
cimen*(1- Proportion of influenza A positive samples
detected by CDC-M)
C) Scenario C - RVP only: Cost of c1 + Cost of c2 (figure 3)
Cost of c1: Cost of RVP*No. of specimen*Proportion of
influenza A positive samples detected by RVP*Proportion
of influenza A positive samples that are seasonal H1/H3
Cost of c2: (Cost of RVP*No. of specimen*Proportion
of influenza A positive samples detected by RVP)*
Figure 2 Scenario B - CDC-M with/without RVP.
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sonal H1/H3)+( Cost of pH1N1 typing*No. of speci-
men*Proportion of influenza A positive samples
detected by RVP*Proportion of influenza A positive
samples that are pH1N1)+[ ( Cost of pH1N1 typing+
Cost of seasonal H1N1 typing)*No. of specimen*Propor-
tion of influenza A positive samples detected by RVP*
(1-Proportion of influenza A positive samples that are
pH1N1 and seasonal H1/H3)]
D) Scenario D - CDC-M only: Cost of d1 + Cost of d2 + Cost
of d3 (figure 4)
Cost of d1: (Cost of CDC-M+ Cost of pH1N1 typing)*No.
of specimen*Proportion of influenza A positive samples
detected by CDC-M*Proportion of influenza A positive
samples that are pH1N1
Cost of d2: (Cost of CDC-M+ Cost of pH1N1 typing+
Cost of seasonal H1/H3 typing)*No. of specimen*Pro-
portion of influenza A positive samples detected by
Figure 3 Scenario C - RVP only.
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are SeasonalH1/H3
Cost of d3: (Cost of CDC-M)*No. of specimen*(1-Pro-
portion of influenza A positive samples detected by
CDC-M)
Results
The median weekly number of specimens tested at
ProvLab during the study was 682 (range: 293-3,876).
The median % of specimens tested positive for one or
more respiratory virus during the study using Scenario
A till June 23, 2009 and Scenario B for the remaining
period was 44.2% (range: 29.2-63.9%). Two peak periods
(mid-May to mid-August) and (late-September to early-
December) were observed for pH1N1 when the weekly
positive rates for influenza A were 29.2% and 53.4%
respectively. Figure 5 shows the relative weekly total
costs of each proposed scenario given the prevalence of
pH1N1 in our jurisdiction during both pandemic waves
of 2009 and the pandemic interwave period.
From Figure 5 it is evident that Scenario D (influenza
A RT-PCR and subtyping alone) was the least expensive
method throughout both waves of the pandemic and the
inter-wave period and the relative weekly total cost of
Figure 4 Scenario D - CDC-M only.
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expensive approach was Scenario C (Testing by RVP fol-
lowed by influenza pH1N1 sub-typing). Both Scenario A
(RVP first, followed by RT-PCR for influenza A on
negative specimens) and Scenario B (influenza A RT-
PCR followed by RVP on influenza A-negative speci-
mens) had similar costs when the rate of influenza A
was low (< 10%) and Scenario A had higher relative cost
as the incidence of influenza peaked during the pan-
demic. Scenario A would have provided more informa-
tion of specimens with influenza A with mixed
respiratory virus infection as compared with Scenario B.
On the other hand, the turn-around time (TAT) of RT-
PCR for influenza A is 24 hours where as the TAT of
RVP is 48 hours, thus Scenario B will provide a faster
report for influenza A positive specimens. Further to
timing issues, the hands-on labor impact of the RVP
assay is greater than that of the RT-PCR for influenza.
Discussion
This manuscript has modeled several scenarios for the
detection of Pandemic (H1N1) 2009, with the two most
expensive scenarios being Scenario A and Scenario B. Pros
and cons of different scenarios are shown in Table 1. Sce-
nario A (RVP with/without CDC-M) consistently had the
highest costs that were maintained throughout the whole
pandemic period, although costs did drop as the % of spe-
cimens positive for influenza A increased. Not only were
the costs high for Scenario A, the labor intensive nature of
the assay and increased turn-around time for influenza A
compared to other methods would make it difficult to
deliver a timely answer to clinicians when compared to
other scenarios. The costs for Scenario B (CDC-M first
with H-typing and FluA-neg samples by RVP) was the sec-
ond most expensive algorithm throughout the pandemic
with costs dropping as the % of specimens positive for
influenza A increased. However, the up-front use of the
CDC-M assay would enable influenza diagnosis to be
undertaken with less technologist hands-on time and a
quicker turn-around time than RVP based methods. Test
cost and increased technologist hands-on-time would
occur during periods outsidet h ei n f l u e n z aAp e a k ,a n d
diagnosis of other respiratory viruses would still be depen-
dent on the use of the RVP.
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Figure 5 Rate of specimens positive for respiratory virus(es), influenza A and Pandemic H1N1 (2009) and the relative total weekly test
cost per specimen for Scenarios A-D during April 19 2009 to April 24, 2010. The relative cost of each algorithm is calculated as the ratio of
each algorithm to the lowest cost of any algorithm for the same time period.
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Scenario D. Scenario C (testing for influenza and respira-
tory virus by RVP only with H-typing) was the third low-
est cost over all pandemic phases with costs crossing
over with Scenario B at the peak. This algorithm would
be focused on using the labor-intensive RVP assay and
would require a longer turn-around-time to influenza A
diagnosis than Scenario B. Furthermore, there have been
some recent questions as to the use of RVP for the pri-
mary diagnosis of influenza A in patient specimens [10].
The least expensive scenario across all phases of the pan-
demic was Scenario D (Influenza A by CDC-M only with
H-typing). This scenario was also less labor intensive
than scenarios focused on RVP and provided a quicker
turn-around time to the diagnosis of influenza A than
scenarios using RVP as the primary diagnostic tool. How-
ever, this scenario does not provide any data on other cir-
culating respiratory viruses which had both diagnostic
and surveillance value.
Outright costs alone should not be the primary driving
force during the decision process regarding which algo-
rithm is used. Other relevant factors in this decision-
making process include needs for test performance data at
the start of the pandemic, test turn-around-time, burden
on laboratory staffing hours, availability of commercial
kits, space available to carry out assays, and overall algo-
rithm performance characteristics [10]. Thus, laborator-
ians may decide to provide tests that are more costly to
the laboratory but provide better patient care and may
even save costs globally in patient care systems [11]. These
increased laboratory test cost per specimen may be recov-
ered in increased efficiency in other areas such as clinical
decision making, infection control and public health prac-
tice [12,13].
The benefit of testing for other respiratory viruses
needs to be determined by each laboratory following
discussion with its client bases. These and other authors
have often experienced that some laboratorians and clin-
icians believe that there is little benefit to testing viruses
other than influenza due to the lack of widespread anti-
virals for other viral pathogens [14]. However, testing
for other viruses fulfills key surveillance roles and may
have patient care and economic benefits in some set-
tings [15-17]. Steps such as cohorting patients based on
Table 1 Benefits of using each influenza A testing scenario during the pandemic
Scenario Description Pros Cons Other comments
A RVP first with typing &Flu
A-neg* samples by CDC-M
and Typing
* Flu A positive samples
not typed by RVP were
also tested by CDC-M for
confirmation
￿ Provide data on the
performance
characteristics of
different diagnostic
assays
￿ Identifies mixed
influenza and other
respiratory infections
￿ Surveillance for other
respiratory viruses
￿ Argument about relevance of
diagnosing other viruses apart
from RSV A/B during a public
health emergency
￿ Resource intense
￿ Labor intensive
￿ May be difficult to stock for
pandemic
￿ Poor turn-around time for
influenza A
￿ After obtaining data for validation
purposes and total virus surveillance, this
approach was replaced by a more cost-
effective and time sensitive diagnostic
approach (Scenario B) which does not
provide the prevalence of mixed infection
with influenza A
B CDC-M first with H-typing
& FluA-neg samples by
RVP
￿ Quicker Turn-around-
time to influenza
diagnosis compared to
RVP-based assays
￿ Scenario drops out
more labor intensive test
as % influenza increases
￿ Influenza-negative
specimens still being
tested for other
respiratory viruses
￿ Will not identify influenza co-
infections with other viruses
￿ May still be considered as
resources intense
￿ Argument about relevance of
diagnosing other viruses apart
from influenza A during a public
health emergency
￿ Some laboratories may find this approach
too resource intense.
￿ Relative cost decrease as % specimen
positive for influenza increases
C RVP only with H-typing ￿ Diagnosis of mixed
infections
￿ Questionable use for influenza
surveillance
￿ Labor intensive
￿ May be difficult to stock for
pandemic
￿ Poor turn-around time for
influenza A
￿ Possible use when no influenza circulating
or influenza prevalence <5% or acceptance
of having missed influenza cases because of
lower sensitivity of RVP
D influenza A by CDC-M only
with H-typing
￿ Less labor-intensive,
￿ Lower cost than RVP
￿ Quicker Turn-around-
time compared to RVP-
based assays
￿ Excellent tool for
testing during peak
pandemic period
￿ Does not allow for identification
of other circulating viruses or co-
infections
￿ Depends on high prevalence of influenza A
and lower prevalence of other viruses or
mixed infections
￿ Role when maximum peaks are seen
(>60% specimen influenza A)
Lee et al. Virology Journal 2011, 8:277
http://www.virologyj.com/content/8/1/277
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the clinical management of patients [18]. Identification
of other viruses my also play a role in the discontinua-
tion of antimicrobial therapy and decreased antibiotic
use in some clinical settings [12].
The identification of trends in viral was easy and read-
i l ya c c e s s i b l et h r o u g ht h eu s eo fD I A Lw h i c hi sap a r t -
nership between Alberta’sP r o v i n c i a lL a b o r a t o r yf o r
Public Health (ProvLab) and the Canadian Network for
Public Health Intelligence (CNPHI). DIAL was founded
by Drs. Jutta Preiksaitis, Bonita Lee and Shamir Mukhi
in 2007 to address critical problems in extracting and
managing laboratory-based data and was created so that
ProvLab staff and other stakeholders would have an
easier method for extracting, interpreting and analyzing
laboratory data. Historically at ProvLab, the extraction
of laboratory data from the Provlab information system
(COHORT) was complex and could only be performed
by computer programmers. Therefore, data was not
easily accessible to laboratory staff, public health practi-
tioners or other stakeholders. Moreover, the extracted
data still required interpretation by laboratory experts to
convert it into clinically meaningful final result. How-
ever, DIAL provides a solution to these problems by
providing a simple web-based interface that enables
users to access, summarize and analyze cleaned and
interpreted real-time laboratory data [7].
Pandemic preparedness involves not only the technical
preparation of laboratories but also an understanding of
both the cost implications of test utilization as well as the
characteristics of each test algorithm. This manuscript
indicates that a single methodology is not applicable to
all conditions and that test characteristics may be as or
more important than test-cost. Also it is notable that the
cost of tests per specimen will vary depending on the
prevalence of influenza A as well as other circulating
viruses. Thus as the prevalence of influenza increases, an
RVP only strategy (Scenario C) will increase in cost while
a strategy that primarily using the CDC protocol with or
without RVP (Scenario B) will decrease in cost. Clinician
as well as patient needs may also have an impact on
which algorithm is chosen as some situations may
require quick turn-around-times (e.g. detection of influ-
enza) while others may require an more comprehensive
assessment of other respiratory viruses (e.g. cohorting
patients with common respiratory infections) [19-21]
This manuscript indicates that an ideal pandemic plan
should allow for the laboratory to effectively shift between
different algorithms as the pandemic progresses and
depending on whether there is a need to identify other
respiratory viral pathogens. The diagnostic and surveil-
lance value in the identification of respiratory viruses sup-
ports the use of a combination of influenza testing and
other RVP tests, or a multiplexed panel alone. The test
volume, the proportion of specimens positive for influenza
A and relative proportion of seasonal versus pH1N1 all
affect the final cost, thus modeling for the optimal
approach while fulfilling surveillance and diagnostic needs
is complex. This movement to an RVP panel alone when
influenza A prevalence is low would rely on effective near
real-time surveillance systems that can provide decision
makers the ability to analyze and review cleaned and inter-
preted laboratory data. In contrast, in a setting with a high
prevalence of influenza, the laboratory leadership might
decide, after consultation with the client base, whether
only testing for influenza would be appropriate [22].
Another cost-saving approach is to stop H-typing of all
specimens at the peak of the pandemic when essentially
over 90% of the positive specimens were pH1N1 which
needs to be balanced with ongoing monitoring and sur-
veillance initiatives. During the peak week of the second
pH1N1 wave, 19-40% of the total cost was used for H-typ-
ing of influenza A positive specimens (data not shown).
Therefore, laboratory planning and preparedness should
include policies and procedures that ensure smooth algo-
rithm transitions at all pre-analytical, analytical and post-
analytical steps of the testing process.
It should also be noted that DIAL has applications
outside of the pandemic and can be used for health care
and public health planning during routine respiratory
seasons. The near-real time capability of this system
provides up-to-date information of circulating respirator
virus and is of great benefit for the trending of respira-
tory virus overtime.
Pandemic planning should be process focused with
well established standard operating procedures to ensure
that staff are able to handle transitions effectively with-
out extensive micromanagement [23,24]. It is also
important to have timely communications to the client
base to indicate changes in algorithms during specific
conditions and the impact of these changes on test
ordering, clinical decision making and patient care [25].
Such real-time decision making requires an interactive
and simple to use data management system that allows
decision makers to have access to the most up-to-date
laboratory data. A system such as DIAL is ideal in this
setting as it harvests real time information from labora-
tory information systems and allows for analysis of
aggregate data [26]. Access to this type of data may
allow decision makers to potentially avoid decision mak-
ing pitfalls such as; uncertainty, prejudice and optimism
bias. However, the authors agree that biases will still
exist even in the presence of DIAL, and decisions may
still be made regardless of the data due to other factors
impacting decision making such as group think, anchor-
ing or choice-supportive bias [27].
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The authors believe that outright costs alone should not
be the primary driving force in deciding which testing
algorithm to choose. For example, an algorithm that uti-
lizes the RVP alone is generally more cost effective than
an algorithm combining both influenza testing and RVP.
However, other factors such as test turn-around-time,
burden on laboratory staffing hours, and overall algo-
rithm performance characteristics should also be
included in the decision making process. For example, a
slightly more costly algorithm involving a combination
of different tests may be chosen to ensure that tests
results are returned to the clinician in a quicker manner
as well as increased information and sensitivity. One
may also argue that this increased laboratory test cost
per specimen may be recovered in increased efficiency
in other areas such as clinical decision making, infection
control and public health practice. Furthermore, this
“trade-off” must be clearly stated to those involved in
global health budgets to avoid a narrow vision where
laboratory costs are separated from other health costs.
A summary of the benefits and drawbacks of each sce-
nario is included in Table 1. During peak periods when
resources are limited and few mixed infections are seen
(>60% influenza A), the authors believe that a scenario
such as Scenario D (influenza A by CDC-M only with
H-typing) focused on CDC-M will allow laboratories to
provide the quickest results with less economic impact.
This might be the last scenario carried out in a public
health emergency when resources (both laboratory and
human) become increasingly limited. In contrast, during
periods of intermediate influenza A prevalence
(40-60%), laboratories will still benefit from Scenario B
(CDC-M first with H-typing & FluA-neg samples by
RVP). Influenza A diagnosis turn-around-times can be
decreased and most testing would not eliminate RVP
testing. However, mixed influenza infections with other
viruses would not be detected and the resources and
space required to carry out this scenario may force
some laboratories closer to Scenario D. In contrast, the
use of RVP alone with H-typing (Scenario C) would be
less expensive than other scenarios but would be very
labor intensive and would increase turn-around times
for influenza A diagnosis. One might utilize Scenario C
w h e nt h ep r e v a l e n c eo fi n f l u e n z aAi s< 5 %a n dt h e
numbers of tests are limited. Such a protocol may be
used after a pandemic period when the pandemic strain
is known not to circulate, but care must be taken not
used this methodology as an approach for surveillance
of a new pandemic wave. There are new questions as to
t h ev a l u eo fu s i n gR V Pa l o n et od i a g n o s ei n f l u e n z aA ,
especially when viral loads in patient specimens drop.
Scenario A (RVP first with typing and influenza A
negative samples by CDC-M and Typing) is the most
expensive of all algorithms and is very labor intensive
with high turn-around-times for influenza A diagnosis.
However, this approach was critical and needed at the
beginning of the pandemic when we were just learning
about the performance characteristics of various diag-
nostic assays for the new influenza strain while obtain-
ing data on total respiratory virus surveillance. Having
access to near real-time cleaned and interpreted labora-
tory using DIAL allowed and enhanced ProvLab deci-
sion-making process so that a cost effective approach
that provided good diagnostic and surveillance data
(Scenario B) can be adopted early in the pandemic.
List of Abbreviations
The following is a list of abbreviations; CDC-M: Centers for Diseases Control
Influenza A Matrix Assay; CNPHI: Canadian Network for Public Health
Intelligence; DFA: Direct fluorescent antibody; DIAL: data integration for
Alberta laboratories; pH1N1: Pandemic (H1N1); ProvLab: Provincial Laboratory
for Public Health; RT-PCR: Reverse transcriptase polymerase chain reaction;
RVP: Luminex respiratory virus panel.
Acknowledgements
The authors would like to thank the DIAL implementation team and
ProvLab staff for their assistance.
Author details
1University of Alberta, Edmonton AB, Canada.
2Canadian Network for Public
Health Intelligence, Public Health Agency of Canada, Winnipeg, MB, Canada.
3Public Health Agency of Canada, Ottawa, Ontario, Canada.
4University of
Calgary, Calgary, AB, Canada.
5Provincial Laboratory for Public Health, Alberta,
Canada.
Authors’ contributions
All authors read and approved the final manuscript.
BL: undertook conceptualization, planning, data analysis, and writing
manuscript. SM: conceptualization and critical revision of manuscript. JMH:
data analysis and revising manuscript. SP: data analysis and revising
manuscript. ML: conceptualization and revising manuscript. SD:
conceptualization, planning, data analysis and writing manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 February 2011 Accepted: 6 June 2011
Published: 6 June 2011
References
1. Public health agency of Canada: The Canadian Pandemic Influenza Plan
for the Health Sector. 2011 [http://www.phac-aspc.gc.ca/cpip-pclcpi/].
2. Drews SJ, Majury A, Jamieson F, Riley G, Mazzulli T, Low DE: Decentralized
molecular diagnostic testing plan for pandemic influenza in the Ontario
Public Health Laboratory system. Can J Public Health 2008, 99:387-390.
3. Hatchette TF, Bastien N, Berry J, Booth TF, Chernesky M, Couillard M,
Drews S, Ebsworth A, Fearon M, Fonseca K, et al: The limitations of point
of care testing for pandemic influenza: what clinicians and public health
professionals need to know. Can J Public Health 2009, 100:204-207.
4. Mahony JB, Hatchette T, Ojkic D, Drews SJ, Gubbay J, Low DE, Petric M,
Tang P, Chong S, Luinstra K, et al: Multiplex PCR tests sentinel the
appearance of pandemic influenza viruses including H1N1 swine
influenza. J Clin Virol 2009, 45:200-202.
5. Pabbaraju K, Wong S, Wong AA, Appleyard GD, Chui L, Pang XL, Yanow SK,
Fonseca K, Lee BE, Fox JD, et al: Design and validation of real-time
reverse transcription-PCR assays for detection of pandemic (H1N1) 2009
virus. J Clin Microbiol 2009, 47:3454-3460.
Lee et al. Virology Journal 2011, 8:277
http://www.virologyj.com/content/8/1/277
Page 10 of 116. StatsCan: Population, urban and rural, by province and territory (Alberta).
2011 [http://www40.statcan.ca/l01/cst01/demo62j-eng.htm].
7. Mukhi S, May-Hadford J, Plitt S, Preiksaitis JK, Lee BE: DIAL: A platform for
real-time laboratory surveillance. Online Journal of Public Health
Informatatics 2010, 3.
8. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ,
Gubareva LV, Xu X, Bridges CB, Uyeki TM: Emergence of a novel swine-
origin influenza A (H1N1) virus in humans. N Engl J Med 2009,
360:2605-2615.
9. Pabbaraju K, Tokaryk KL, Wong S, Fox JD: Comparison of the Luminex
xTAG respiratory viral panel with in-house nucleic acid amplification
tests for diagnosis of respiratory virus infections. J Clin Microbiol 2008,
46:3056-3062.
10. Pabbaraju K, Wong S, Lee B, Tellier R, Fonseca K, Louie M, Drews SJ:
Comparison of a singleplex real-time RT-PCR assay and multiplex
respiratory viral panel assay for detection of influenza “A” in respiratory
specimens. Influenza Other Respi Viruses 2011, 5:99-103.
11. Adcock PM, Stout GG, Hauck MA, Marshall GS: Effect of rapid viral
diagnosis on the management of children hospitalized with lower
respiratory tract infection. Pediatr Infect Dis J 1997, 16:842-846.
12. Oosterheert JJ, van Loon AM, Schuurman R, Hoepelman AI, Hak E, Thijsen S,
Nossent G, Schneider MM, Hustinx WM, Bonten MJ: Impact of rapid
detection of viral and atypical bacterial pathogens by real-time
polymerase chain reaction for patients with lower respiratory tract
infection. Clin Infect Dis 2005, 41:1438-1444.
13. Fox JD: Respiratory virus surveillance and outbreak investigation. J Clin
Virol 2007, 40(Suppl 1):S24-S30.
14. Nichols WG, Peck Campbell AJ, Boeckh M: Respiratory viruses other than
influenza virus: impact and therapeutic advances. Clin Microbiol Rev 2008,
21:274-90, table.
15. Woo PC, ChiuS S, Seto WH, Peiris M: Cost-effectiveness of rapid diagnosis
of viral respiratory tract infections in pediatric patients. J Clin Microbiol
1997, 35:1579-1581.
16. Barenfanger J, Drake C, Leon N, Mueller T, Troutt T: Clinical and financial
benefits of rapid detection of respiratory viruses: an outcomes study. J
Clin Microbiol 2000, 38:2824-2828.
17. Rocholl C, Gerber K, Daly J, Pavia AT, Byington CL: Adenoviral infections in
children: the impact of rapid diagnosis. Pediatrics 2004, 113:e51-e56.
18. Doherty JA, Brookfield DS, Gray J, McEwan RA: Cohorting of infants with
respiratory syncytial virus. J Hosp Infect 1998, 38:203-206.
19. Ruest A, Michaud S, Deslandes S, Frost EH: Comparison of the Directigen
flu A+B test, the QuickVue influenza test, and clinical case definition to
viral culture and reverse transcription-PCR for rapid diagnosis of
influenza virus infection. J Clin Microbiol 2003, 41:3487-3493.
20. Ong GM, Wyatt DE, O’Neill HJ, McCaughey C, Coyle PV: A comparison of
nested polymerase chain reaction and immunofluorescence for the
diagnosis of respiratory infections in children with bronchiolitis, and the
implications for a cohorting strategy. J Hosp Infect 2001, 49:122-128.
21. Ieven M: Currently used nucleic acid amplification tests for the detection
of viruses and atypicals in acute respiratory infections. J Clin Virol 2007,
40:259-276.
22. Nicoll A, Ammon A, Amato GA, Ciancio B, Zucs P, Devaux I, Plata F,
Mazick A, Molbak K, Asikainen T, et al: Experience and lessons from
surveillance and studies of the 2009 pandemic in Europe. Public Health
2010, 124:14-23.
23. Vongphrachanh P, Simmerman JM, Phonekeo D, Pansayavong V, Sisouk T,
Ongkhamme S, Bryce GT, Corwin A, Bryant JE: An early report from newly
established laboratory-based influenza surveillance in Lao PDR. Influenza
Other Respi Viruses 2010, 4:47-52.
24. Meltzer MI, McNeill KM, Miller JD: Laboratory surge capacity and
pandemic influenza. Emerg Infect Dis 2010, 16:147-148.
25. Bradt DA, Epstein J: The rational clinician in a pandemic setting. Med J
Aust 2010, 192:87-89.
26. Paneth-Pollak R, Schillinger JA, Borrelli JM, Handel S, Pathela P, Blank AS:
Using STD electronic medical record data to drive public health
program decisions in New York City. Am J Public Health 2010,
100:586-590.
27. McCaughey D, Bruning NS: Rationality versus reality: the challenges of
evidence-based decision making for health policy makers. Implement Sci
2010, 5:39.
doi:10.1186/1743-422X-8-277
Cite this article as: Lee et al.: Determination of the relative economic
impact of different molecular-based laboratory algorithms for respiratory
viral pathogen detection, including Pandemic (H1N1), using a secure
web based platform. Virology Journal 2011 8:277.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lee et al. Virology Journal 2011, 8:277
http://www.virologyj.com/content/8/1/277
Page 11 of 11